Stockscreener 앱 받기
9.59
4.47%
0.41
시간 외 거래:
9.45
-0.14
-1.46%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa
Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology
US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
Raymond James maintains $18 target on RGNX after trial data - Investing.com
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline News & Insights
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK
REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa
Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com
REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat
5 Analysts Have This To Say About Regenxbio - Benzinga
Morgan Stanley Reiterates "Overweight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - Kilgore News Herald
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World
Analysts Offer Predictions for REGENXBIO FY2024 Earnings - MarketBeat
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World
HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat
HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey
REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance UK
Regenxbio: Q3 Earnings Snapshot - The Washington Post
RegenXBio Reports Progress Amid Revenue Decline - TipRanks
Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - StockTitan
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
1.89%
2.08%
자본화:
|
볼륨(24시간):